TABLE 2.

Drug resistance of E. coli cells harboring plasmids carrying putative drug transporter ORFs^a

Compound	MIC (μg/ml) without plasmid	MIC (μg/ml) with plasmid carrying ORF for transporter of type:
		MF								MATE (pUCydhE)	RND					SMR		ABC (pUCybjYZ)
		pUCfsrb	pUCmdfA	pUCyceE	pUCbcrc	pUCemrAB	pUCemrD	pUCynfM	pUCyebQ		pUCacrAB	pUCyegMNOBd	pUCacrD	pUCacrEF	pUCyhiUV	pUCemrE	pUCydgFE
Chloramphenicol	0.39	0.39	6.25	0.39	0.39	0.39	0.39	0.39	0.39	0.78	3.13	0.39	0.39	0.39	0.39	0.39	0.39	0.39
Tetracycline	0.39	0.39	0.78	0.39	1.56	0.39	0.39	0.39	0.39	0.39	3.13	0.39	0.39	0.39	0.39	0.39	0.39	0.39
Minocycline	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	3.13	0.20	0.20	0.20	0.20	0.20	0.20	0.20
Erythromycin	3.13	3.13	3.13	3.13	3.13	3.13	3.13	3.13	3.13	3.13	100	3.13	3.13	3.13	25	3.13	3.13	25
Nalidixic acid	0.78	0.78	0.78	0.78	0.78	0.78	0.78	0.78	0.78	0.78	3.13	1.56	0.78	0.78	0.78	0.78	0.78	0.78
Norfloxacin	0.025	0.025	0.20	0.025	0.025	0.025	0.025	0.025	0.025	0.20	0.20	0.05	0.025	0.025	0.025	0.025	0.025	0.025
Enoxacin	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.39	0.39	0.05	0.05	0.05	0.05	0.05	0.05	0.05
Kanamycin	6.25	6.25	6.25	6.25	12.5	6.25	6.25	6.25	6.25	6.25	6.25	6.25	12.5	6.25	6.25	6.25	6.25	6.25
Vancomycin	200	200	200	200	200	200	200	200	200	200	200	200	200	200	200	200	200	200
Fosfomycin	1.56	1.56	1.56	6.25	6.25	1.56	1.56	1.56	1.56	3.13	1.56	3.13	1.56	1.56	1.56	1.56	1.56	1.56
Doxorubicin	3.13	3.13	12.5	3.13	3.13	3.13	3.13	3.13	3.13	25	>200	3.13	3.13	6.25	25	3.13	3.13	3.13
Novobiocin	1.56	1.56	1.56	1.56	1.56	1.56	1.56	1.56	1.56	1.56	100	25	6.25	1.56	1.56	1.56	1.56	1.56
Rifampin	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25	12.5	6.25	6.25	6.25	6.25	6.25	6.25	6.25
Trimethoprim	3.13	6.25	12.5	3.13	3.13	3.13	3.13	3.13	0.78	12.5	>100	3.13	3.13	3.13	3.13	3.13	3.13	3.13
Acriflavine	12.5	12.5	100	12.5	25	12.5	12.5	3.13	12.5	12.5	>200	12.5	12.5	100	12.5	200	12.5	12.5
Crystal violet	1.56	1.56	1.56	1.56	1.56	1.56	1.56	1.56	1.56	1.56	12.5	1.56	1.56	1.56	3.13	3.13	1.56	1.56
Ethidium bromide	12.5	12.5	50	12.5	12.5	12.5	12.5	12.5	12.5	25	>400	12.5	12.5	50	50	100	12.5	12.5
Rhodamine 6G	6.25	6.25	6.25	6.25	6.25	12.5	6.25	6.25	6.25	6.25	400	6.25	6.25	25	100	6.25	6.25	6.25
Methylviologen	100	100	100	100	100	200	100	100	100	100	100	100	100	100	100	200	100	100
TPP	6.25	6.25	25	6.25	6.25	6.25	6.25	6.25	6.25	200	400	6.25	6.25	6.25	25	6.25	6.25	6.25
CCCP	6.25	12.5	6.25	6.25	6.25	50	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25	6.25
Benzalkonium	3.13	3.13	3.13	3.13	3.13	3.13	6.25	3.13	3.13	6.25	100	6.25	3.13	3.13	6.25	6.25	3.13	3.13
SDS	50	50	50	50	50	100	100	50	50	50	>400	200	>400	100	200	50	100	50
Deoxycholate	1,250	1,250	1,250	1,250	1,250	40,000	1,250	1,250	1,250	40,000	>40,000	>40,000	>40,000	5,000	5,000	1,250	5,000	1,250

^aValues in bold differ significantly from the KAM3 control strain value. MICs were measured without IPTG, so that the ORFs were expected to be expressed under the control of the endogenous promoters. Data are not shown for pUCemrKY, which carries emrK/Y and evgS/A genes. This plasmid conferred resistance to doxorubicin (MIC, 100 μg/ml), rhodamine 6G (100 μg/ml), benzalkonium (25 μg/ml), erythromycin (12.5 μg/ml), crystal violet (6.25 μg/ml), TPP (25 μg/ml), deoxycholate (5,000 μg/ml), fosfomycin (3.13 μg/ml), novobiocin (3.13 μg/ml), acriflavine (25 μg/ml), ethidium bromide (25 μg/ml), methylviologen (200 μg/ml), and SDS (100 μg/ml). Multidrug resistance conferred by pUCemrKY is due to overexpression of evgA, emrK/Y genes confer deoxycholate resistance (33). pUCyajR, pUCyceL, pUCydeA, pUCydeF, pUCydhC, pUCydiM, pUCyidY, pUCyieO, pUCyjiO, pUCcusA, pUCsugE, pUCmdlAB, pUCyddA, pUCyojIH, and pUCyhiH did not alter MIC values. 

^bpUCfsr conferred fosmidomycin resistance (MIC, 0.39 μg/ml for KAM3 versus 12.5 μg/ml for KAM3/pUCfsr). 

^cpUCbcr conferred bicyclomycin resistance (MIC, 25 μg/ml for KAM3 versus 400 μg/ml for KAM3/pUCbcr). 

^dpUCyegMNOB carries both RND- (yegM/N/O) and MF-type (yegB) ORFs. Resistance conferred by pUCyegMNOB is due to overexpression of RND genes (unpublished data).